Although p73a induces many of the same cellular events as p53, it is structurally distinct from p53 in that it possesses a unique COOH-terminal domain. To dissect the function of this domain, we performed yeast twohybrid screening of a HeLa cDNA library using residues 552-636 of p73a as bait. Among the clones that showed a specific interaction with p73a was AMP-activated protein kinase a (AMPKa). Additional yeast two-hybrid assays indicated that the bc-binding domain of AMPKa is critical for the interaction with p73a. The interaction was further confirmed in vitro by glutathione S-transferase pull-down, and in vivo by immunoprecipitation and immunofluorescence microscopy. Transient coexpression of AMPKa resulted in downregulation of the effect of p73a, but not of p53, on various p53-responsive promoters. Chromatin immunoprecipitation indicated p73a-dependent recruitment of AMPKa to the p21WAF1 promoter. Treatment with 5-aminoimidazole-4-carboxamide ribonucleotide, an agonist of AMPKa, and expression of dominant-negative versions of AMPKa revealed that the repression of p73a was independent of AMPKa kinase activity. In addition, cisplatin-induced growth repression was impaired when AMPKa was overexpressed. Upon the knock down of AMPKa by siRNA, the induction of p21WAF1 by p73a was significantly increased. Taken together, these data indicate that AMPKa specifically regulates p73a by a direct interaction without affecting its phosphorylation status. From these data, we speculate that AMPKa may provide a molecular clue to understand the repressive role of the C-terminus of p73a in transcription and DNA damage response.
Introduction
The p53 family is composed of p53 and the recently identified proteins p73 and p63. Similar to p53, p73 and p63 can form homo-oligomers, bind to canonical p53 DNA-binding sites, modulate the transcription of p53-responsive genes and suppress growth or induce apoptosis when overexpressed in certain human tumors (Jost et al., 1997; Kaghad et al., 1997; Osada et al., 1998; Yang et al., 1998) . Each protein also shares significant homology with p53 in its transactivation domain, DNAbinding domain (DBD) and oligomerization domain. However, the sequences C-terminal to the DBD are highly divergent. For example, the C-terminus of p73a, similar to that of p63a, possesses an additional 216-amino acid segment (residues 421-636) that includes a sterile a motif (residues 484-549), which may be involved in protein-protein interactions or developmental regulation (Thanos and Bowie, 1999) . Interestingly, p73b, another splicing variant, lacks the full C-terminus of p73, which includes most of the sterile a motif domain. The C-terminal differences among the various family members may reflect significant divergence in signaling and function (McGrath et al., 2001) . Indeed, p73 differentially transactivates some but not all p53-responsive genes in response to cellular stress (Dietz et al., 2002) , as shown by in silico genome-wide analysis (Sbisa`et al., 2007) . Furthermore, gene disruption studies strongly suggest that the biological functions of p73 and p53 may differ under physiological conditions . Intriguingly, the C-terminal deletion of p73a results in significantly increased transcription of luciferase reporters harboring p53-responsive promoters and enhancement of the sub-G1 population in p53-null cells (Ozaki et al., 1999; Liu and Chen, 2005) , suggesting that the C-terminus of p73a may act as a transcriptional repressor, probably through direct association with an unidentified nuclear corepressor.
To investigate the role of the C-terminus of p73a in transcriptional repression, we first performed yeast twohybrid screening of a human cDNA library using the C-terminus of p73a, and found that p73 is functionally associated with AMP-activated protein kinase a (AMPKa). AMPK is a heterotrimeric serine/threonine kinase consisting of a catalytic a subunit (a1 or a2) and noncatalytic, regulatory b and g subunits, all of which are required for full kinase activity (Kemp et al., 2003) . AMPK has been primarily described as a metabolic sensor that responds to intracellular ATP depletion induced by various metabolic stresses, and it is directly activated by increases in the AMP:ATP ratio (Hardie et al., 1998 (Hardie et al., , 1999 Kemp et al., 1999) . Recent studies suggest that it can also be activated by upstream AMPK kinases such as the serine/threonine kinase LKB1, which phosphorylates the a subunit of AMPK at Thr 174 (at Thr 172 for a2) (Woods et al., 2003; Lizcano et al., 2004; Shaw et al., 2004) , and possibly by Ca 2 þ /CaMdependent protein kinase kinase, which functions independently of AMP but phosphorylates the same residue in AMPK (Hawley et al., 2005; Hurley et al., 2005; Woods et al., 2005) . Once activated, AMPK phosphorylates several target proteins, which are mostly cytoplasmic enzymes involved in glucose and lipid metabolism. AMPK also regulates gene expression either directly or indirectly (Leclerc et al., 2002) . Direct regulation of gene transcription by AMPK is likely achieved through the phosphorylation of transcription factors (PPARa, PPARg, HNF4a, ChREBP, HIF-1 and p53), cofactors (p300, PGC-1 and TRIP6) and the basal transcriptional machinery (Pol I) in the nucleus (Lee et al., 2003; Leff, 2003; Bronner et al., 2004; Jones et al., 2005; Solaz-Fuster et al., 2006) . Of the catalytic a subunits found in AMPK, a1 is located mainly in the cytoplasm, whereas a2 is detected preferentially in the nucleus (Salt et al., 1998; Turnley et al., 1999; da Silva Xavier et al., 2000) , further indicating that the a subunit may modulate AMPK-regulated gene transcription. The suggested role of AMPK in transcriptional regulation also comes from the observation that Snf1, a yeast homolog of AMPK, acts as a histone kinase in cooperation with the histone acetyltransferase Gcn5 (Lo et al., 2001) .
Here, we describe the identification of AMPKa, which interacts with the C-terminus of p73a, and the functional significance of this interaction in the regulation of the transcriptional activity of p73a. AMPKmediated repression of p73a activity, albeit kinase activity-independent, could account for the role of the C-terminus of p73a in transcriptional repression as reported in the literature (Ozaki et al., 1999; Liu and Chen, 2005) . Thus, we propose that AMPKa mediates the repressive effect of the C-terminus of p73a on transcription.
Results

Isolation of AMPKa
A yeast two-hybrid system was used to identify proteins that interact with residues 49-636 of p73a (minus the N-terminal transactivation domain) using a HeLa cDNA library (Figure 1a) . One of the clones obtained from the screen was AMPKa1 (Figure 1b) . Additional screening using LexA DBD-fused p53 family members and VP16 AD-fused AMPKa1 (and its deletion) indicated that the C-terminal bg-binding domain of AMPKa1 is critical for its interaction with p73a and p63a, but not with p53, p63g or p73b, all of which lacked transactivation domains (Figure 1c) . To map the AMPKa interaction domain of p73a, the coding regions of several p73a deletion derivatives and AMPKa (a1 and a2) were fused to the LexA DBD and VP16 AD, respectively. Our results indicate that the C-terminus (residues 552-636) of p73a is critical for its interaction with AMPKa ( Figure 1d ) and that the C-terminus of p73a interacts with the C-terminal bg-binding domain of AMPKa.
Interaction in vitro and in mammalian cells
To confirm the specificity of the interaction between the p53 family and AMPKa in vitro and in mammalian cells, we performed glutathione S-transferase (GST) pulldown assays, immunoprecipitation (IP) assays and immunofluorescence microscopy. For our GST pulldown assays, each p53 family member was cloned into pGEX4T, a GST expression vector. Flag-tagged fulllength AMPKa1 and a2 were translated in vitro with rabbit reticulocyte lysate. The GST-fused p53 proteins were expressed in Escherichia coli, purified and mixed separately with Flag-tagged AMPKa. Consistent with our yeast two-hybrid data, Flag-tagged AMPKa1 and a2 were retained only by GST-p63a and p73a (Figure 2a ).
For our IP assays, H1299 cells were cotransfected with each green fluorescent protein (GFP)-fused p53 family member and the full-length Flag-tagged AMPKa (a1 or a2) constructs. As H1299 cells are p53-null and express almost no endogenous p73a (Di Como et al., 1999) , the p53 family members were transfected as GFP fusions. IP with an anti-GFP antibody and subsequent western blotting (WB) with an anti-Flag antibody confirmed the specificity of the interaction between p73a and AMPKa1 ( Figure 2b ) and a2 (Figure 2c ). The interaction between overexpressed GFP-p73a and endogenous AMPKa2 was shown by IP with anti-GFP antibody, and subsequent WB with anti-AMPKa2 antibodies (Figure 2d ). Furthermore, the interaction between endogenous p73a and AMPKa2 was determined (Supplementary Figure 1) . Additional IP and WB indicated that p63a also interacts with AMPKa1 and a2 (Figure 2e) .
To determine the subcellular localizations of AMPKa and p73a in vivo, GFP-tagged p73a was transiently transfected into H1299 cells. As reported by others (Salt et al., 1998; Turnley et al., 1999; da Silva Xavier et al., 2000) , endogenous AMPKa1 was mainly located in the cytoplasm, whereas AMPKa2 were detected in the nucleus. When cells expressing GFP-p73a were stained with anti-AMPKa1 antibody and Texas Red-conjugated anti-rabbit IgG, AMPKa1 was found in the nucleus with p73a ( Figure 3a) . As expected, GFP-p73a and AMPKa2 were colocalized in the nucleus (Figure 3b ).
Effect of AMPKa on the transcriptional activity of p73a
Before investigating the significance of the physical interaction between AMPKa and p73a, we determined whether AMPKa alone showed autonomous transcriptional activity when recruited to a promoter. To this end, Gal4 DBD-fused AMPKa (a1 or a2) was constructed and cotransfected with a Gal4-responsive luciferase reporter gene into H1299 cells. As shown in Figure 4a , overexpression of Gal4-AMPKa resulted in a significant reduction of luciferase activity, suggesting that AMPKa may function as a transcriptional corepressor. Next, to determine whether the interaction of AMPKa with p73a is functionally relevant, the effect of AMPKa on the transcriptional activity of p73a and p53 was investigated using a p53 family-responsive Baxluciferase reporter. With increasing expression of AMPKa1, the transcriptional activity of p73a was gradually reduced, whereas that of p53 was unchanged (Figure 4b ). AMPKa2 gave a similar result (Figure 4c ). Reporter assays in other cell lines also showed similar data ( Supplementary Figure 2a , HeLa; Supplementary  Figure 2c , U2OS). In general, AMPKa2 had a stronger repressive effect than AMPKa1, probably because of its location in the nucleus. Furthermore, AMPKa2 had no effect on the transcriptional activity of p73b and p73a (residues 1-499), which are devoid of the AMPKabinding domain (Figure 4d ). Similarly, both AMPKa1 and a2 repressed the transcriptional activity of p63a (data not shown). In assays using other p53 familyresponsive luciferase reporters (p21WAF1, Mdm2, NOXA and cyclin G), both AMPKa1 and a2 significantly repressed p73a-induced transcription without affecting p53 activity (data not shown). Combined with our interaction data, these results suggest that AMPKa is a novel corepressor of p73a that acts through the C-terminus of p73a.
AMPKa kinase activity is not required for p73a repression Several assays were performed to investigate the possible role of the kinase activity of AMPKa in transcriptional Figure. (d) Mapping of the domains in p73a responsible for its association with AMPKa. For the yeast two-hybrid assays, the coding regions of the p73a deletion derivatives and AMPKa (a1 and a2) were fused to the LexA DBD and VP16 AD, respectively. TAD, transcriptional activation domain; DBD, DNA-binding domain; OD, oligomerization domain; BD, basic regulatory domain; SAM, sterile a motif.
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Y-G Lee et al repression. When a known activator of AMPK, 5-aminoimidazole-4-carboxamide ribonucleotide (AICAR), was added to H1299 cells transfected with the p73a expression vector and a Bax-luciferase reporter, no effect on p73a-induced transcription was observed ( Figure 5a ). Next, three different versions of AMPKa2 with mutations in the kinase domain were constructed and used for reporter assays followed by transient transfection into H1299 cells: D157A and K45R, dominant negatives; T172A, inactive; and T172D, constitutively active (Stein et al., 2000; Chen et al., 2003) . Similar to wild-type AMPKa2, all of the mutants repressed the transcriptional activity of p73a , and as expected, the activity of p53 was unaffected by AICAR or the AMPKa2 mutants. Additional assays revealed that the repressive effect of each mutant was similar to that of wild-type AMPKa (Figures 5e and f). Collectively, these data show that the kinase activity of AMPKa is not required for repression of p73a activity.
Effect of AMPKa on the expression of p21WAF1
To correlate the role of AMPKa in transcriptional repression with its function in vivo, H1299 cells were first transfected with Flag-tagged AMPKa2 and p53 or the p73a expression vector, together with a p21WAF1-luciferase reporter. Consistent with the data obtained using a Bax-luciferase reporter, both AMPKa1 and a2 specifically repressed p73a-induced transcription of the p21WAF1 reporter in H1299 cells ( and AMPKa. H1299 cells were transfected with GFP-tagged p63a and/or Flag-tagged AMPKa1 or a2 and subjected to IP and WB as described. AMPK, AMP-activated protein kinase; GFP, green fluorescent protein.
To guard against nonphysiological effects, the effect of knocking down AMPKa expression was monitored by treating H1299 cells with siRNA. The p73a-activated p21WAF1-luciferase activity was substantially increased by AMPKa2 siRNA but not by control siRNA (Figure 6d, left) . Next, the effect of knocking down AMPKa expression on the expression of endogenous p21WAF1 was determined by expressing p73a in H1299 cells. When AMPKa2 siRNA was used, AMPKa2 expression was greatly reduced, and this was accompanied by an increase in p21WAF1 expression (Figure 6d, right) . In comparison, b-actin expression was not affected.
To test whether the AMPKa-mediated repression of p21WAF1 induction occurs through recruitment of AMPKa to the chromatin-integrated, endogenous p21WAF1 promoter, chromatin immunoprecipitation (ChIP) assays were performed. To this end, H1299 cells stably expressing Flag-tagged AMPKa2 were transiently transfected with Flag-tagged p53 or p73a. Chromatin DNA fragments were then precipitated with the indicated antibodies and amplified with primers selective for the p53/p73a-response element (p53RE) in the p21WAF1 promoter. For specificity, a primer set for RAR response element was used. When overexpressed, not p73a and AMPKa2, but RAR was recruited to the RAR response element (Figure 6e, top) . However, ChIP assays using a primer set for p53RE indicated that both p53 and p73a were recruited to the p21WAF1 promoter (Figure 6e , bottom left). As determined by precipitation with antiAMPKa2 antibodies, AMPKa2 was recruited to the p21WAF1 promoter only when p73a was overexpressed (Figure 6e, bottom right). As AMPKa2 was expressed in H1299 cells (Figure 2d ), AMPKa2 could be recruited to the p21WAF1 promoter. When AMPKa2 was overexpressed, the recruitment of AMPKa2 was more evident. Together, these results suggest that in vivo AMPKa is specifically recruited to the p53RE in the p21WAF1 promoter through its specific association with p73a, where it represses p73a-activated p21WAF1 transcription.
Function of AMPKa in vivo
The downregulation of p21WAF1 is implicated in the upregulation of cell growth by perturbing cell cycle arrest. Our data indicated that AMPKa represses 
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Y-G Lee et al p21WAF1 expression; therefore, we sought to determine whether AMPKa overexpression would affect cisplatin (CDDP)-induced growth suppression. For this purpose, we generated U2OS cells stably expressing AMPKa2 and treated them with cisplatin, a DNA damaging agent. In response to cisplatin, both p73a and p53 were activated in the parental U2OS cells regardless of the presence of AMPKa2 ( Figure 7a) ; however, the cisplatin-induced expression of p21WAF1 was significantly reduced in AMPKa2-expressing U2OS cells. An 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazonium) bromide (MTT) assay was used to monitor the effect of AMPKa2 on cell viability. In the absence of cisplatin, AMPKa2 had no obvious effect on cell growth; however, in the presence of cisplatin, the growth of the AMPKa2-expressing cells exceeded that of the parental cells (Figure 7b) . To measure the effect of AMPKa2 on inducing apoptosis, a cell death detection ELISA Plus quantifying DNA fragmentation was employed in H1299 cells. AMPKa2 alone had no significant effect on both endogenous and p53-induced DNA fragmentation. However, p73a-induced DNA fragmentation was greatly impaired by AMPKa2 overexpression (Figure 7c) . To support the significance of the interaction between AMPKa and p73a in CDDP resistance, further quantitative DNA fragmentation assays were performed using p73a siRNA in U2OS cells. AMPKa2 overexpression with control siRNA resulted in approximately 70% CDDP resistance, while no obvious AMPKa2 effect was observed when p73a was knocked down (Figure 7d ). These data suggest that AMPKa may mediate cell survival by selectively repressing p73a activity in response to DNA damage conditions. Figure 4 Negative effect of AMPKa on the transcriptional activity of p73a. Relative luciferase (Luc) activity was determined by a luciferase assay after normalizing to the observed b-galactosidase activity. Fold-luciferase activity indicates the relative ratio obtained in the presence and absence of the Gal4, p53 or p73 expression vector, depending on the experimental conditions. All data are presented as the means±s.d. of three experiments. (a) Autonomous transcriptional repression by AMPKa. Gal4 DBD-empty or Gal4 DBD-AMPKa1 or a2 (0.2, 0.4 and 0.8 mg) was introduced into H1299 cells with a Gal4-responsive 17mer-tk-luciferase reporter (0.1 mg). (b) Effect of AMPKa1 on the transcriptional activity of p53 and p73a. H1299 cells were transiently cotransfected with a Baxluciferase reporter (0.1 mg), Flag-p53 or -p73a (0.1 mg), and increasing amounts (0.2, 0.4 and 0.8 mg) of the AMPKa1 expression vector. (c) Effect of AMPKa2 on the transcriptional activity of p53 and p73a. The experiment described in (b) was repeated using AMPKa2. (d) Effect of AMPKa2 on the transcriptional activity of p73b and a p73a fragment (residues 1-499). The experiment described in (b) was repeated using variants of p73. AMPK, AMP-activated protein kinase.
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Discussion
Here, we investigated the mechanisms that differentially regulate p73a and p53. Gene disruption studies have shown that the biological functions of p73a and p53 differ; for example, p73a-null mice are distinct from p53-deficient mice, which are prone to tumor formation, in that they exhibit defects in neurological and pheromone sensory pathways (Yang et al., 2000) . Still, p73a and p53 show structural similarities in their transactivation, DNA-binding and oligomerization domains, and they share several target genes, including p21WAF1, Bax, Mdm2, cyclin G and NOXA. However, p73a possesses additional residues at its C-terminus. On the basis of the fact that a p73a mutant devoid of its C-terminus significantly stimulated the transcription of constructs containing p53-responsive promoters and enhanced the sub-G1 population in p53-null cells , a dominant-negative mutant of AMPKa2, on the transcriptional activity of p53 and p73a. (c) Effect of K45R, another dominant-negative mutant of AMPKa2, on the transcriptional activity of p53 and p73a. The same amounts were used as described in (b). (d) Effect of T172A, an inactive mutant of AMPKa2, on the transcriptional activity of p53 and p73a. The same amounts were used as described in (b). (e and f) Effect of mutations in AMPKa2 on its autonomous activity in the absence (e) and presence (f) of AICAR. Gal4-luciferase assays were performed as described, using 0.8 mg of Gal4 or the following Gal4-AMPKa2 mutants: a, Gal4; b, Gal4-wild-type AMPKa2; c, D157A; d, K45R; e, T172A; f, T172D (constitutively active). AICAR, 5-aminoimidazole-4-carboxamide ribonucleotide; AMPK, AMP-activated protein kinase. (Ozaki et al., 1999; Liu and Chen, 2005) , we speculated that the C-terminus of p73a may mediate transcriptional repression through a direct association with an unidentified nuclear corepressor. By yeast two-hybrid screening, we found that AMPKa interacts with the C-terminus of p73a (amino acids 552-636) through its C-terminal bg-binding domain, which is remote from its N-terminal kinase domain. After confirming the interaction in vitro and in mammalian cells, we found that AMPKa specifically represses the transcriptional activity of p73a, but not of p53. In addition, the repressive effect of AMPKa2 was greater than that of AMPKa1, probably due to its nuclear localization. Surprisingly, the AMPKa-mediated repression of p73a activity was independent of its kinase activity as shown using AICAR, a known agonist of AMPK, and various AMPKa2 mutants (D157A and K45R, dominant negatives; T172A, inactive; and T174D, constitutively active). It was recently suggested that AMPK can be activated by Ca 2 þ /CaM-dependent protein kinase kinase independently of AMP (Hawley et al., 2005; Hurley et al., 2005; Woods et al., 2005) . Similar to AICAR, STO-609, a selective inhibitor of Ca 2 þ /CaMdependent protein kinase kinase, was not effective in the repression of p73a by AMPKa (data not shown). These observations suggest that AMPKa, independent of its kinase activity, functions as a transcriptional repressor of p73a and that this repressive effect is mediated by direct interaction of AMPKa with p73a through their C-terminal domains. This finding is reminiscent of the kinase-independent transcriptional coactivation of PPARa by AMPKa (Bronner et al., 2004) . Histone deacetylation by histone deacetylase has been implicated in transcriptional repression (Wang et al., 2004) . In addition, SIRT1, a mammalian homolog of yeast Sir2, was recently shown to suppress the transcriptional activity of p73a (Dai et al., 2007) . Not only tricostatin A, a broad histone deacetylase inhibitor, but also the SIRT1 inhibitor splitomicin had no effect on AMPKa-mediated p73a repression (data not shown), suggesting that AMPKa represses p73a activity independent of either histone or p73a deacetylation. AMPKa interacts with the C-terminal domain of RNA polymerase II through a serine/arginine-rich domain in its C-terminus (Bentley, 1999) . This suggests that AMPKa, through its C-terminal domain, may interfere with the functional association between p73a and RNA polymerase II, which is required for the transcriptional activity of p73a. The suggested role of AMPKa in transcriptional regulation comes from the finding that Snf1, a yeast homolog of AMPKa, is a histone kinase that mediates transcriptional regulation in yeast (Lo et al., 2001) . However, no data are currently available to show whether mammalian AMPKa acts as a histone kinase. Interestingly, our study indicates that AMPKa exhibits a repressive effect on transcription when tethered to a Gal4-responsive promoter and that it is recruited to the p21WAF1 promoter through its interaction with p73a. Thus, these data raise the possibility that AMPKa affects transcription by modifying histone phosphorylation, although it remains to be determined which residues and histones are targeted by AMPKa.
It was recently reported that AMPK activation induces the phosphorylation of p53 on serine 15 (in human; serine 18 in mouse) resulting in cell-cycle arrest (Imamura et al., 2001; Jones et al., 2005) . In addition, AMPK-induced p53 activation promotes cell survival in response to glucose starvation, which is distinct from p53 activation in response to DNA damage. Under our assay conditions, neither AICAR nor mutant AMPKa affected the activation of exogenous p53 in H1299 cells. Similarly, we found that the kinase activity of AMPKa is not required for p73a repression. As the AMPK phosphorylation site in p53 is not conserved in p73a, AMPK activation may not be required for p73a repression. Our data indicate that AMPKa suppresses both p73a-activated Bax transcription and cisplatininduced, p73a-activated p21WAF1 expression, thereby promoting cell survival and proliferation in response to cisplatin. Therefore, we propose a common theme between AMPK-induced p53 activation and AMPKmediated p73a repression in promoting cellular survival in response to glucose deprivation and DNA damage, respectively. Both AMPK and p73 are implicated in neurodevelopment and neuronal survival in response to various stresses (Pozniak et al., 2000 (Pozniak et al., , 2002 Culmsee et al., 2001) . In this respect, our observations may be of significance to determine whether AMPKa regulates neuronal survival by cooperating with p73a in response to death signals in the brain.
Materials and methods
Cell lines and cell culture H1299, HeLa and U2OS cells were maintained in RPMI1640 medium supplemented with 5% heat-inactivated fetal bovine serum and Antibiotic-Antimycotic (all from Gibco BRL, Gaithersburg, MD, USA) in a 5% CO 2 atmosphere at 37 1C. The U2OS cells stably expressing AMPKa were selected in medium treated with G418 (Gibco BRL). Stock solutions of G418 and cisplatin (Amersham Pharmacia Biotech, Piscataway, NJ, USA) were prepared at 2 mg/ml in H 2 O.
Plasmids and cloning
All cDNAs were constructed according to standard methods and were verified by sequencing. The yeast expression plasmids used in the two-hybrid assays are described elsewhere (Kim et al., 2002) . Deletion mutants of the desired genes were created by PCR and were subcloned into pBTM116 (encoding LexA DBD) or pASV3 (VP16 AD). Flag (2 Â )-tagged p53 family and AMPKa1 and a2 genes were cloned into pcDNA3 (Invitrogen, Carlsbad, CA, USA). Gal4-tagged AMPKa1 and a2 were cloned into pG4MpolyII. All AMPKa mutants were created by PCR and were verified by sequencing. GFP-tagged constructs were subcloned into pEGFP-C3 (BD Biosciences, Palo Alto, CA, USA), and pGEX4T (Amersham Pharmacia Biotech) was used to create GST-fused proteins.
Yeast two-hybrid screening and assays A human HeLa cDNA library (Matchmaker, BD Biosciences) in the prey plasmid pGAD10 was screened for proteins that interact with p73, using the yeast reporter strain L40. The experimental procedures were the same as those described earlier (Kim et al., 2002) except that a p73a fragment (residues 49-636), subcloned into pBTM116, was used as bait. To map the interaction domains in AMPKa and p73a, deletion derivatives of AMPKa and p73a were fused with the VP16 AD by subcloning into pASV3. To determine the specificity of the interaction, other p53 family members, including p53 (residues 43-393), p63a (residues 59-676), p63g (residues 59-448) and p73b (residues 49-499), were subcloned into pBTM116. The resulting VP16 AD-AMPKa fusion vectors were cointroduced with the pBTM116 derivatives encoding the LexA DBD-p53 family fusions into L40 cells. The level of interaction was determined by quantitative b-galactosidase (b-gal) assays.
GST pull-down assays GST fusions of p53, p63a and p73a were expressed in E coli and purified on glutathione-Sepharose beads (Amersham Pharmacia Biotech). Full-length AMPKa1 and a2 were synthesized in vitro using rabbit reticulocyte lysate (Promega, Madison, WI, USA). Glutathione-Sepharose beads were equilibrated with A100 binding buffer (Kim et al., 2002) . Approximately equimolar concentrations of GST or GST-p53, -p63a or -p73a were reacted with 10 ml of Flag-AMPKa1 or a2 for 30 min. Pre-equilibrated glutathione-Sepharose beads were added and the sample was further incubated for 1 h. The beads were then washed with binding buffer. The bound proteins Figure 7 AMPKa modulates cell survival in response to DNA damage. (a) Effect of AMPKa2 on cisplatin-induced p21WAF1 expression. U2OS cells stably expressing Flag-empty or Flag-AMPKa2 were selected and treated with 2.5 mg/ml cisplatin (CDDP). After 2 days of treatment, the cells were harvested and their lysates were subjected to western blotting (WB) using the indicated antibodies. (b) Effect of AMPKa2 on cellular proliferation. Cells were treated with CDDP for the times indicated, and viability was determined by MTT assay. The data are presented as the means ± s.d. of three experiments. (c) Effect of AMPKa2 on apoptosis. H1299 cells were transiently transfected with p53, p73a, AMPKa2 alone and together. Induction of apoptosis was quantified using cell death detection ELISA (Roche Diagnostics Korea). (d) Effect of p73a knock down on AMPKa2-mediated CDDP resistance. U2OS cells were transfected with Flag-empty or Flag-AMPKa2 and then treated with 2.5 mg/ml cisplatin (CDDP) and control or p73a siRNA for 48 h. Inlet indicates p73a level determined by WB. Figure 6 Effect of AMPKa on p21WAF1 expression. (a and b) Effect of AMPKa1 (a) and AMPKa2 (b) on p53-and p73a-induced p21WAF1 transcription. H1299 cells were transiently cotransfected with a p21WAF1-luciferase reporter (0.1 mg), Flag-p53 or -p73a (0.1 mg), and increasing amounts (0.2, 0.4 and 0.8 mg) of the AMPKa1 or a2 expression vector. Subsequent luciferase assays were conducted as described in Figure 4 . All data are presented as the means ± s.d. of three experiments. (c) Effect of AMPKa2 on p21WAF1 expression induced by p53 and p73a. H1299 cells were transiently cotransfected with Flag-p53 or -p73a (0.1 mg), and increasing amounts (0.2, 0.4 and 0.8 mg) of the AMPKa1 expression vector. The expression of p21WAF1, p53 and p73a was monitored by WB (top) and RT-PCR (bottom) using b-actin and GAPDH as loading controls, respectively. (d) Effect of knocking down AMPKa2 on p73a-activated p21WAF1 expression. H1299 cells were transfected with Flag-p73a and a p21WAF1-luciferase reporter, and treated with 100 pmol of AMPKa2 siRNA or control siRNA. The effect of the knock down was monitored by luciferase assays (left). Endogenous p21WAF1 expression was measured by WB in cells lacking the p21WAF1-luciferase reporter (right). The knock down of AMPKa2 was verified by WB. (e) p73a-dependent recruitment of AMPKa2 to the chromatin-associated p21WAF1 promoter. The p53/p73a-response element (p53RE) and RAR response element (RARE) were represented in the p21WAF1 promoter. H1299 cells were transfected with Flag-p53, -p73a and/or the AMPKa2 expression vector. Soluble chromatin was prepared and immunoprecipitated with antibodies against either Flag or AMPKa2. The final DNA pellets were amplified by PCR using primers that cover the p53RE or RARE in the p21WAF1 promoter. AMPK, AMP-activated protein kinase; GAPDH, glyceraldehyde-3-phosphate dehydrogenase.
were eluted by boiling in sample buffer and were detected by SDS-PAGE followed by WB.
WB and IP analysis
Both analyses were performed as described earlier (Kim et al., 2002) . Primary antibodies used were mouse monoclonal antiFlag M2 antibody (F3165; Sigma, St Louis, MO, USA), rabbit polyclonal anti-GFP antibody (sc-8334; Santa Cruz Biotechnology, Santa Cruz, CA, USA), mouse monoclonal anti-p21WAF1 antibody (sc-6246; Santa Cruz Biotechnology), mouse monoclonal anti-p73a antibody (NeoMarkers, Union City, CA, USA), rabbit polyclonal anti-p53 antibody (sc-6243; Santa Cruz Biotechnology), rabbit polyclonal anti-AMPKa2 antibody (Upstate, Chicago, IL, USA) and mouse monoclonal anti-b-actin antibody (A1978; Sigma). Secondary antibodies were peroxidase-conjugated mouse or rabbit IgG (Amersham Pharmacia Biotech). The protein bands were detected with an ECL system (Amersham Pharmacia Biotech). For IP, H1299 cells were transfected with the GFP-p53 family (p53, p73a or p63a) and Flag-AMPK (a1 or a2) expression vectors. Following precipitation of the GFP-tagged p53 proteins with precleared protein A/G-Agarose beads (Santa Cruz Biotechnology) and anti-GFP rabbit polyclonal antibodies, the immune complexes were released from the beads and subjected to 10% SDS-PAGE. The precipitates were then analysed by WB using mouse anti-Flag antibody.
Immunofluorescence microscopy H1299 cells seeded on 12-well plates were transfected with GFP-p73a. After 24 h of seeding, the cells were washed with phosphate-buffered saline (PBS), fixed with 4% paraformaldehyde in PBS for 1 min at room temperature and permeabilized for 4 min in PBS containing 0.5% Triton X-100 at 4 1C. After washing, the cells were incubated with anti-AMPKa1 or anti-AMPKa2 antibody (rabbit polyclonal; Upstate) in blocking buffer (PBS and 2% bovine serum albumin) for 1 h and incubated with Texas Red-conjugated anti-rabbit IgG (Amersham Pharmacia Biotech). After washing, the cells were visualized under a fluorescence microscope (AX70; Olympus Optical Co., Tokyo, Japan). Hoechst (Sigma) staining was used to visualize chromosomal DNA in the nucleus.
Transient transfection and luciferase assay H1299 cells were transiently transfected with a Gal4-tkluciferase or Bax-luciferase reporter gene and with an SV40-driven b-gal expression vector as an internal control. Depending on the experimental conditions, Gal4-AMPKa1 (or a2), p53, p73a, p73a (residues 1-499), p73b or an AMPKa2 mutant (D159A, K45R or T174A) expression vector was cotransfected using Lipofectamine Plus reagent (Invitrogen). When needed, different concentrations (0.1, 0.5 and 1.0 mM) of AICAR (Sigma) were added. Luciferase activity was measured by adding 20 ml of Luciferin to 30 ml of the lysates using an analytical luminescence luminometer, according to the manufacturer's instructions (Promega). b-gal activity was determined in 96-well plates that were read at 405 nm. Luciferase activity was normalized to the b-gal activity.
ChIP ChIP was performed as described earlier (Lee et al., 2007) . Briefly, H1299 cells grown in Dulbecco's modified Eagle's medium plus 5% fetal bovine serum for 1 day were transfected as indicated. The cells were then cross-linked with formaldehyde and swollen on ice in SDS lysis buffer. Nuclei supernatants were collected and diluted in ChIP dilution buffer. The fragmented chromatin mixture was subsequently incubated with 2 ml of either mouse monoclonal anti-Flag antibody or anti-AMPKa2 antibody and protein A/G-Agarose beads. The cross-linked and precipitated chromatin complexes were recovered and reversed according to Upstate's protocol (Upstate). The DNA pellets were recovered and analysed by PCR using a pair of primers encompassing the p21WAF1 promoter region (214 bp). The primers used were (forward) 5 0 -GGGAGATTGGTTCAATGTCC-3 0 and (reverse) 5 0 -CCTGGAGCACCTAGACACCC-3 0 . For specificity, a primer set encompassing RAR response element in p21WAF1 promoter was used as described (Cho et al., 2006) .
Construction of cells stably expressing Flag-AMPK
An expression vector for Flag-AMPKa2 was constructed by subcloning PCR-amplified cDNA into the G418-resistant plasmid pcDNA3. U2OS cells were transfected with either Flag-AMPKa2 or empty pcDNA3 in the presence of Lipofectamine Plus reagent (Invitrogen) for 24 h and then treated with 700 mg/ml G418 (American Pharmacia Biotech). After 3-5 days, the cells were incubated with fresh culture medium containing G418, and G418-resistant colonies were selected after 2 weeks.
MTT and apoptosis assay
Control and AMPKa2-expressing U2OS cells were seeded on a 96-well plate. After 24 h, the cells were treated with 2.5 mg/ml cisplatin (Amersham Pharmacia Biotech). The effect of cisplatin on cell growth was monitored by MTT (Sigma) assay as described earlier (Cho et al., 2006) . For apoptosis assay, H1299 cells were transiently transfected with p53, p73a, AMPKa2 alone and together for 2 days. DNA fragmentation, an indicative of apoptosis was quantified with Cell Death Detection ELISA kit (Roche Diagnostics Korea, Seoul, Korea) according to the manufacturer's recommendations as described elsewhere (Weiske and Huber, 2006) . The absorbance at A 405 was measured using a 96-well plate reader.
RNA interference
The sequences of the custom siRNA duplexes for AMPKa2 and p73a were as described elsewhere (Pilon et al., 2004; Lau et al., 2008) . The siRNA duplex controls used were designed and supplied by Invitrogen: sense 5 0 -CCUACGCCAC CAAUUUCGU(dTdT)-3 0 and antisense 5 0 -ACGAAAUUG GUGGCGUAGG(dTdT)-3 0 . Transfection of the siRNAs was performed with Lipofectamine 2000 in Opti-MEM I reducedserum medium (Invitrogen) according to the manufacturer's instructions.
Abbreviations AMPK, AMP-activated protein kinase; AICAR, 5-aminoimidazole-4-carboxamide ribonucleotide; DBD, DNA-binding domain; GST, glutathione S-transferase; ChIP, chromatin immunoprecipitation; GFP, green fluorescent protein; b-gal, b-galactosidase; MTT, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazonium) bromide.
